Xylem director granted 1,711 RSUs
Morelli Mark D reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Morelli Mark D reported acquisition or exercise transactions in this Form 4 filing.
Xylem Inc. director Mark D. Morelli received an award of 1,711 shares of common stock in the form of restricted stock units valued at $116.88 per share. These units are scheduled to vest in full on the trading day before the 2027 Annual Meeting of Shareholders, with settlement deferred until his Separation from Service. Following this award, he directly holds 8,026 shares, including additional shares from dividend reinvestment.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 1,711 | $116.88 | $200K |
Footnotes (2)
- F1. Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in full on the trading day prior to the 2027 Annual Meeting of Shareholders. The Reporting Person has elected to defer the settlement of the RSU Award until Separation from Service.
- F2. Includes additional shares due to dividend reinvestment.
Key Figures
Key Terms
restricted stock units financial
Xylem 2011 Omnibus Incentive Plan financial
Separation from Service financial
dividend reinvestment financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Xylem (XYL) director Mark D. Morelli report?
At what price were the Xylem (XYL) restricted stock units granted to Mark D. Morelli?
When do Mark D. Morelli’s Xylem (XYL) restricted stock units vest?
Is Mark D. Morelli’s Xylem (XYL) Form 4 transaction an open-market buy or a compensation grant?
AI-generated analysis. How Rhea-AI works. Not financial advice.